Content Block Tag: NRG-BR009: OFSET

‘Text/HTML’ of page ‘NRG-BR009: OFSET’

Am I eligible for this study? Premenopausal women who have early-stage breast cancer that is sensitive to hormones and is HER2-negative, with an Oncotype DX Recurrence Score® equal to or less than 25 (if they have positive axillary lymph nodes at surgery) or with an Oncotype DX Recurrence Score® between 16 and 25 (if they […]

‘Text/HTML’ of page ‘NRG-BR009: OFSET’

About This Study NRG-BR009, also known as the “OFSET” trial, is a clinical study trying to determine whether the chance of breast cancer returning would be less if chemotherapy is added to hormonal therapy with an aromatase inhibitor and ovarian function suppression. This study is being done to answer the following question: Will the […]

‘Text/HTML’ of page ‘NRG-BR009: OFSET’

Clinical Studies FAQ

‘Text/HTML’ of page ‘NRG-BR009: OFSET’

The NRG-BR009 Study FAQ